Table 2 Reduction over Months 1 to 6 in mean monthly MHDs with associated symptoms
LFEM Average of Months 1–6 (95% CI) | HFEMAverage of Months 1–6 (95% CI) | |||||
|---|---|---|---|---|---|---|
Monthly MHDs with: | Placebo (N = 295) | GMB 120 mg (N = 150) | GMB 240 mg (N = 145) | Placebo (N = 580) | GMB 120 mg (N = 286) | GMB 240 mg (N = 283) |
All MHDs | −0.9 (−1.4,-0.5) | −2.8 (−3.3, − 2.2) | −2.3 (− 2.8, − 1.7) | −3.4 (− 3.8, 3.0) | −5.4 (− 5.9, − 4.9) | −5.5 (−6.0, − 4.9) |
p vs placebo | <.001 | <.001 | <.001 | <.001 | ||
Acute medication use | − 0.8 (− 1.2, − 0.4) | − 2.4 (− 2.9, − 2.0) | −2.1 (− 2.6, − 1.7) | −2.7 (− 3.1, − 2.7) | −4.6 (− 5.1, − 4.2) | −4.6 (− 5.0, − 4.2) |
p vs placebo | <.001 | <.001 | <.001 | <.001 | ||
Prodromal symptoms | −0.6 (− 0.9, − 0.4) | −1.1 (− 1.4, − 0.7) | −1.1 (− 1.4, − 0.7) | −1.4 (− 1.6, − 1.1) | − 2.2 (− 2.6, − 1.9) | −2.0 (− 2.4, − 1.7) |
p vs placebo | .006 | .006 | <.001 | <.001 | ||
Aura | −0.4 (− 0.6, − 0.2) | −0.8 (− 1.0, − 0.5) | −0.7 (− 0.9, − 0.4) | − 1.3 (− 1.5, − 1.0) | −1.8 (− 2.0, − 1.5) | −1.8 (− 2.1, − 1.5) |
p vs placebo | .005 | .055 | <.001 | <.001 | ||
Photophobia and phonophobia | −0.5 (− 0.9, − 0.1) | −1.9 (− 2.4, − 1.4) | −1.7 (− 2.2, − 1.2) | − 2.5 (− 2.9, − 2.1) | − 4.2 (− 4.7, − 3.7) | −4.1 (− 4.6, − 3.6) |
p vs placebo | <.001 | <.001 | <.001 | <.001 | ||
Nausea and/or vomiting | −0.2 (− 0.5, 0.1) | −0.9 (− 1.2, − 0.6) | −0.9 (− 1.2, − 0.6) | −1.5 (− 1.8, − 1.2) | −2.6 (− 2.9, − 2.2) | −2.4 (− 2.8, − 2.1) |
p vs placebo | <.001 | <.001 | <.001 | <.001 | ||